other material
confidence high
sentiment negative
materiality 0.90
Core Scientific restates financials for multiple periods due to improper asset capitalization, reports Q4 2025 results
Core Scientific, Inc./tx
- Restatement for Non-Reliance Periods from June 30, 2024 through Sept 30, 2025 due to improper capitalization of assets committed to demolition during mining-to-HPC conversion.
- Material weakness identified in internal control over financial reporting; Marcum LLP to revise opinion to adverse on 2024 internal controls.
- Q4 2025 revenue $79.8M vs $94.9M Q4 2024; colocation revenue rose to $31.3M from $8.5M; self-mining revenue fell to $42.2M.
- Net income $216.0M vs net loss $291.1M in Q4 2024, driven by non-cash fair value gain of $330.3M on warrant and CVR liabilities.
- Capital expenditures $279.2M in Q4 2025, with $226.2M funded by CoreWeave; liquidity of $533.4M including $311.4M cash and $222.0M bitcoin.